Novo Nordisk will sell introductory doses of Wegovy and Ozempic for $199 per month to US cash-pay patients in a move aimed at rival Eli Lillys Zepbound. The two-month offer covers 0.25 mg and 0.5 mg doses and runs from November 17, 2025, to March 31, 2026. Novo shares dipped over 1% premarket, though retail sentiment stayed bullish.